THERAPY DOSSIER · th-d6bb2588f3e4

Proteolytically active myelin basic protein, delivered as recombinant protein or by adeno-associated virus

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00079495 ↗PHASE2completed

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients With Relapsing Multiple Sclerosis

Multiple Sclerosis

Enrolment: 150 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26081148 ↗2015Reported benefit

Myelin Basic Protein Cleaves Cell Adhesion Molecule L1 and Improves Regeneration After Injury.

MouseSpinal cord injuryUnspecifiedC57BL/6 and myelin basic protein-deficient shiverer miceApplication to the injured spinal cord and femoral nerve, and virus-mediated expression at the lesion site; in utero injection for the developmental study

Model: Spinal cord injury and femoral nerve injury in adult mice, with an additional developmental study in shiverer mice

Application of proteolytically active myelin basic protein raised transmembrane L1 fragment levels, promoted remyelination and improved functional recovery after spinal cord and femoral nerve injury, whereas antibody blockade impaired recovery and proteolytically inactive protein had no benefit.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…